Desrosiers Martin Y, Kilty Shaun J
The Department of Otolaryngology, Hôpital Hôtel-Dieu, Université de Montreal, Montreal, Quebec, Canada.
Rhinology. 2008 Mar;46(1):3-14.
It is estimated that over 500,000 individuals in the United States currently suffer from chronic rhinosinusitis (CRS), which has persisted or recurred despite maximal medical therapy and endoscopic sinus surgery (ESS). Management of these individuals remains uncertain, as recent published guidelines on CRS do not extend to this population.
Our objective is to provide a framework for the management of patients who fail standard therapy for CRS while providing recommendations based on the strength of the evidence for alternative medical therapies that can be used for the treatment of recurrent CRS. This guideline targets ENT physicians and allergists managing this increasingly frequent clinical situation and attempts to assist them in selecting from the increasing array of potential therapies available. To this end, factors contributing to the pathophysiology of post-ESS CRS are reviewed to identify method of action of existing and potential therapies and recommendations are made for their use.
Given the accessibility of the sinus cavities after ESS, topical therapies are privileged. Saline spray or irrigation is recommended for all patients. Corticosteroids in oral or topical forms are recommended for controlling the inflammatory component, while the use of a short term course of oral or topical antibiotics are recommended mainly for the treatment of exacerbations. Long-term therapy with oral macrolides is also recommended as an alternative therapy. Desensitization with acetylsalicylic acid (ASA) for individuals with documented ASA sensitivity is recommended where available, while revision surgery, anti-leukotriene agents and intravenous immunoglobulins are options in management in selected patients. Antifungal therapy is not recommended. No recommendations for potentially experimental strategies are made in the absence of published experience and safety data in human subjects.
据估计,美国目前有超过50万个体患有慢性鼻-鼻窦炎(CRS),尽管接受了最大程度的药物治疗和鼻内镜鼻窦手术(ESS),病情仍持续或复发。这些个体的治疗方案仍不明确,因为最近发布的CRS指南并未涵盖这一人群。
我们的目标是为CRS标准治疗失败的患者提供一个管理框架,同时根据替代药物治疗的证据强度提供建议,这些替代药物可用于治疗复发性CRS。本指南针对处理这种日益常见临床情况的耳鼻喉科医生和过敏症专科医生,试图帮助他们从越来越多的潜在治疗方法中进行选择。为此,对ESS后CRS病理生理学的影响因素进行了综述,以确定现有和潜在治疗方法的作用机制,并对其使用提出建议。
鉴于ESS后鼻窦腔易于接近,局部治疗具有优势。建议所有患者使用盐水喷雾或冲洗。推荐口服或局部使用皮质类固醇来控制炎症成分,而短期口服或局部使用抗生素主要推荐用于治疗病情加重。长期口服大环内酯类药物也推荐作为替代治疗。对于有阿司匹林(ASA)敏感记录的个体,如有条件,建议进行ASA脱敏治疗,而翻修手术、抗白三烯药物和静脉注射免疫球蛋白是部分患者管理中的选择。不推荐抗真菌治疗。在缺乏人体受试者已发表的经验和安全性数据的情况下,不对潜在的实验性策略提出建议。